Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O’Reilly DA, Cunningham D, Wadsley J, Dar-by S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDon-ald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hack-ert T, Jackson R, Buchler MW, European study group for pancreatic cancer (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a 8 multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024
2. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA et al (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836e47
3. Loehrer AP, Ferrone CR (2016) Treatment of locally advanced pancreatic ductal adenocarcinoma. Dig Surg 33:343–350
4. National Comprehensive Cancer Network web-site. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
5. Verbeke CS (2008) Resection margins and R1 rates in pancreatic cancer–are we there yet? Histopathology 52(7):787e96